Clinical trials in Hoofddorp – page 113

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hoofddorp at a glance

1 940

clinical trials

Research sites1

Quick filters

1 940 trials in Hoofddorp

Open in trial search

Osteogenesis imperfecta

Not recruiting

Study on the Safety and Effectiveness of BOOST Cells for Treating Severe Osteogenesis Imperfecta in Children Before and After Birth

InvestigationalNo placebo

Study on the Safety and Effectiveness of BOOST Cells for Treating Severe Osteogenesis Imperfecta in Children Before and After Birth

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Sponsor:Karolinska Institutet

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Encorafenib and Binimetinib for Patients with BRAF V600-Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Encorafenib and Binimetinib for Patients with BRAF V600-Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

K-ras gene mutation+3

Not recruiting

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Children Aged 6-11 with Moderate-to-Severe Atopic Dermatitis

Registered drugNo placebo

Study on Tralokinumab for Children Aged 6-11 with Moderate-to-Severe Atopic Dermatitis

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Tralokinumab
Sponsor:Leo Pharma A/S

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Colorectal cancer metastatic+2

Not recruiting

Study of Irinotecan with FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Cancer Metastases

Registered drugNo placebo

Study of Irinotecan with FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Cancer Metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Irinotecan Hydrochloride Trihydrate
Sponsor:Catharina Ziekenhuis Stichting

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:RLY-4008
Sponsor:Elevar Therapeutics Inc.

Contact Research Centre

Gastrointestinal stromal tumour

Not recruiting

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ripretinib
Sponsor:Deciphera Pharmaceuticals Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

Advanced/Metastatic Breast Cancer Treatments
Urothelial Cancer Therapies
Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

B-Cell Lymphoma Treatments
Myelofibrosis Therapies
Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

Weight Management Interventions
Surgical Techniques
Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the Netherlands All countries